Lenalidamide
Phase 3Small molecule
Lenalidamide is one of 20 small molecule programs targeting Complex Regional Pain Syndrome. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Complex Regional Pain Syndrome
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Suboxone
IIndivior Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Low-Dose Naltrexone
SStanford University
Approved
Duragesic
CCephalon
Phase 3
Zometa
PfizerPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Xylocaine
MMEDRx USA, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lenalidamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMayo Clinic